Which field walking test should be used to assess functional exercise capacity in lung cancer? an observational study

BMC Pulmonary Medicine

Louis Irving⁴  Maeve Sorohan²  Tim Dimitriadis⁴  Joel Martin²  Selina M. Parry¹  Linda Denehy³  Catherine L. Granger³ 

[1]Department of Physiotherapy, The University of Melbourne, 161 Barry Street, Parkville, VIC, Australia

[2]Department of Physiotherapy, Royal Melbourne Hospital, Grattan Street, Parkville, VIC, Australia

[3]Institute for Breathing and Sleep, Heidelberg Road, Heidelberg, VIC, Australia

[4]Department of Respiratory and Sleep Medicine, Royal Melbourne Hospital, Grattan Street, Parkville, VIC, Australia

关键词: Cardio-pulmonary exercise test;    Endurance shuttle walk test;    Six-minute walk distance;    Incremental-shuttle walk test;    Exercise capacity;    Lung cancer;   

Others  :  1222544
DOI  :  10.1186/s12890-015-0075-2

 received in 2015-01-12, accepted in 2015-07-16,  发布年份 2015

【 摘 要 】

Background

There is emerging evidence regarding the efficacy of exercise training to improve exercise capacity for individuals with non-small cell lung cancer (NSCLC). Cardiopulmonary exercise testing (CPET) is the gold standard measure of exercise capacity; however this laboratory test has limitations for use in research and clinical practice. Alternative field walking tests are the six-minute walk test (6MWT), incremental-shuttle walk test (ISWT) and endurance-shuttle walk test (ESWT); however there is limited information about their clinimetric properties in NSCLC. Aims: In NSCLC to determine the 1) criterion validity of the 6MWT, ISWT and ESWT against CPET; 2) construct validity of the 6MWT, ISWT and ESWT against measures of function, strength, respiratory function and health-related quality of life (HRQoL); and 3) clinical applicability of the tests.

Methods

Twenty participants (40 % male, mean ± SD age 66.1 ± 6.5 years) with stage I-IIIb NSCLC completed the 6MWT, ISWT, ESWT and CPET within six months of treatment. Testing order was randomised. Additional measures included Eastern Cooperative Oncology Group Performance-Status (ECOG-PS, function), respiratory function, hand-grip dynamometry and HRQoL. Correlations and regression analyses were used to assess relationships.

Results

The ISWT demonstrated criterion validity with a moderate relationship between ISWT distance and CPET peak oxygen consumption (r = 0.61, p = 0.007). Relationships between CPET and six minute walk distance (6MWD) (r = 0.24, p = 0.329) or ESWT time (r = 0.02, p = 0.942) were poor. Moderate construct validity existed for the 6MWD and respiratory function (forced vital capacity % predicted r = 0.53, p = 0.019; forced expiratory volume in the first second % predicted r = 0.55, p = 0.015). There were no relationships between the walking tests and measures of function, strength or HRQoL. The ESWT had a ceiling effect with 18 % reaching maximum time. No floor effects were seen in the tests. The mean ± SD time required to perform the individual 6MWT, ISWT and ESWT was 12.8 ± 2.5, 14.7 ± 3.7 and 16.3 ± 5.0 min respectively; in comparison to CPET which was 51.2 ± 12.7 min. Only one assessor was required to perform all field walking tests and no adverse events occurred.

Conclusions

The ISWT is a promising measure of functional exercise capacity in lung cancer. Findings need to be confirmed in a larger sample prior to translation into practice.

【 授权许可】

   
2015 Granger et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Ferlay J, Dikshit R, Elser S, Mathers C, Rebelo M, Parkin DM. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, Lyon, France; 2013. Available from: http://globocan. iarc.fr, accessed on 10/11/2014. 2013
• [2]Jones L, Eves ND, Haykowsky M, Freedland SJ, Mackey JR. Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol. 2009; 10(6):598-605.
• [3]Tanaka K, Akechi T, Okuyama T, Nishiwaki Y, Uchitomi Y. Impact of dyspnea, pain, and fatigue on daily life activities in ambulatory patients with advanced lung cancer. J Pain Symptom Manage. 2002; 23(5):417-23.
• [4]Granger CL, McDonald CF, Irving L, Clark RA, Gough K, Murnane A et al.. Low physical activity levels and functional decline in individuals with lung cancer. Lung Cancer. 2014; 83:292-9.
• [5]Maruyama R, Tanaka J, Kitagawa D, Ohta R, Yamauchi K, Ayabe H et al.. Physical assessment immediately after lobectomy via miniposterolateral thoracotomy assisted by videothoracoscopy for non-small cell lung cancer. Surg Today. 2011; 41(7):908-13.
• [6]Ostroff J, Krebs P, Coups EJ, Burkhalter JE, Feinstein MB, Steingart RM et al.. Health-related quality of life among early-stage, non-small cell, lung cancer survivors. Lung Cancer. 2011; 71(1):103-8.
• [7]Hung R, Krebs P, Coups EJ, Feinstein MB, Park BJ, Burkhalter J et al.. Fatigue and functional impairment in early-stage non-small cell lung cancer survivors. J Pain Symptom Manage. 2011; 41(2):426-35.
• [8]Granger CL, McDonald CF, Berney S, Chao C, Denehy L. Exercise intervention to improve exercise capacity and health related quality of life for patients with Non-small cell lung cancer: a systematic review. Lung Cancer. 2011; 72(2):139-53.
• [9]Crandall K, Maguire R, Campbell A, Kearney N. Exercise intervention for patients surgically treated for Non-Small Cell Lung Cancer (NSCLC): a systematic review. Surg Oncol. 2014; 23:17-30.
• [10]Cavalheri V, Tahirah F, Nonoyama M, Jenkins S, Hill K. General and Supportive Care: Exercise training for people following lung resection for non-small cell lung cancer – a cochrane systematic review. Cancer Treat Rev. 2014; 40:585-94.
• [11]Fleg J, Piña IL, Balady GJ, Chaitman BR, Fletcher B, Lavie C et al.. Assessment of functional capacity in clinical and research applications - An advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association. Circulation. 2000; 102(13):1591-7.
• [12]Jones L, Eves ND, Mackey JR, Peddle CJ, Haykowsky M, Joy AA et al.. Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer. Lung Cancer. 2007; 55(2):225-32.
• [13]Jones LW, Eves ND, Peterson BL, Garst J, Crawford J, West MJ et al.. Safety and feasibility of aerobic training on cardiopulmonary function and quality of life in postsurgical nonsmall cell lung cancer patients: a pilot study. Cancer. 2008; 113(12):3430-9.
• [14]Jones LW, Watson D, Herndon JE, Eves ND, Haithcock BE, Loewen G et al.. Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer. Cancer. 2010; 116(20):4825-32.
• [15]Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D et al.. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014; 44(6):1428-46.
• [16]Jones L, Eves ND, Haykowsky M, Joy AA, Douglas PS. Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations. Lancet Oncology. 2008; 9(8):757-65.
• [17]Portney L, Watkins M. Foundations of clinical research applications to practice. 2nd ed. Prentice Hall, Upper Saddle River, New Jersey; 2000.
• [18]England R, Maddocks M, Manderson C, Wilcock A. Factors influencing exercise performance in thoracic cancer. Respir Med. 2012; 106(2):294-9.
• [19]de Vet H, Terwee CB, Mokkink LB, Knol DL. Measurement in Medicine - A Practical Guide. Cambridge University Press, Cambridge, UK; 2011.
• [20]Granger C, McDonald CF, Parry SM, Oliveira CC, Denehy L. Functional capacity, physical activity and muscle strength of individuals with non-small cell lung cancer: a systematic review of outcome measures and their measurement properties. BMC Cancer. 2012; 13:135. BioMed Central Full Text
• [21]Jenkins SC. 6-Minute walk test in patients with COPD: clinical applications in pulmonary rehabilitation. Physiotherapy. 2007; 93(3):175-82.
• [22]Bellet N, Adams L, Morris N. Systematic review: The 6-minute walk test in outpatient cardiac rehabilitation: validity, reliability and responsiveness—a systematic review. Physiotherapy. 2012; 98(4):277-86.
• [23]Singh S, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax. 1992; 47:1019-24.
• [24]Singh S, Morgan MD, Hardman AE, Rowe C, Bardsley PA. Comparison of oxygen uptake during a conventional treadmill test and the shuttle walking test in chronic airflow limitation. Eur Respir J. 1994; 7(11):2016-20.
• [25]von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP et al.. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Bull World Health Organ. 2007; 85(11):867-72.
• [26]Mokkink L, Terwee CB, Knol DL, Stratford PW, Alonso J, Patrick DL, et al. The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Med Res Methodol. 2010;10:22–2.
• [27]Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP et al.. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Br Med J. 2009; 339:b2700.
• [28]Moher D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement… reprinted with permission from the Annals of Internal Medicine from Mother D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther. 2009; 89(9):873-80.
• [29]Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003; 167(10):1451.
• [30]Society AT. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166:111-7.
• [31]Singh SJ, Puhan MA, Andrianopoulos V, Hernandes NA, Mitchell KE, Hill CJ et al.. An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J. 2014; 44(6):1447-78.
• [32]Borg G. Psychophysical bases for perceived exertion. Med Sci Sports Exerc. 1982; 14(5):377-81.
• [33]Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ et al.. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008; 31(2):416-68.
• [34]Miller M, Hankinson J, Brusasco V. Standarisation of spirometry. Eur Respir J. 2005; 26:319-38.
• [35]MacIntyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V et al.. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2007; 24(3):S65-82.
• [36]Jones N. Clinical Exercise Testing. 3rd ed. W.B. Saunders, Philadelphia; 1988.
• [37]Oken M, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al.. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55.
• [38]Innes E. Handgrip strength testing: a review of the literature. Aust Occup Ther J. 1999; 46(3):120-40.
• [39]Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al.. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-76.
• [40]Colinet B. A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson’s index. Br J Cancer. 2005; 93(10):1098-105.
• [41]Norman G. Likert scales, levels of measurement and the “laws” of statistics. Adv Health Sci Educ Theory Pract. 2010; 15(5):625-32.
• [42]Win T, Jackson A, Groves AM, Sharples LD, Charman SC, Laroche CM. Comparison of shuttle walk with measured peak oxygen consumption in patients with operable lung cancer. Thorax. 2006; 61(1):57-60.
• [43]Skumlien S, Hagelund T, Bjørtuft O, Ryg MS. A field test of functional status as performance of activities of daily living in COPD patients. Respir Med. 2006; 100(2):316-23.
• [44]Brunelli A, Kim AW, Berger KI, Addrizzo-Harris DJ. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2014; 143(5):e166S-90.
• [45]Granger CL, Holland AE, Gordon IR, Denehy L. Minimal important difference of the six-minute walk distance in lung cancer. Chron Respir Dis. 2015; 12(2):146-54.
• [46]Cheville A, Novotny PJ, Sloan JA, Basford JR, Wampfler JA, Garces YI et al.. The value of a symptom cluster of fatigue, dyspnea, and cough in predicting clinical outcomes in lung cancer survivors. J Pain Symptom Manage. 2011; 42(2):213-21.
• [47]Handy J, Asaph JW, Skokan L, Reed CE, Koh S, Brooks G et al.. What happens to patients undergoing lung cancer surgery? Outcomes and quality of life before and after surgery. Chest. 2002; 122(1):21-30.
• [48]Saad I, Botega N, Toro I. Predictors of quality-of-life improvement following pulmonary resection due to lung cancer. Sao Paulo Med J. 2007; 125(1):46-9.
• [49]Pierce R, Copland JM, Sharpe K, Barter CE. Preoperative risk evaluation for lung cancer resection: predicted postoperative product as a predictor of surgical mortality. Am J Respir Crit Care Med. 1994; 150(4):947-55.
• [50]Kasymjanova G, Correa JA, Kreisman H, Dajczman E, Pepe C, Dobson S et al.. Prognostic value of the six-minute walk in advanced non-small cell lung cancer. J Thoracic Oncol. 2009; 4(5):602-7.
• [51]Jones L, Hornsby WE, Goetzinger A, Forbes LM, Sherrard EL, Quist M et al.. Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer. Lung Cancer. 2012; 76(2):248-52.
• [52]Denehy L, Hornsby WE, Herndon JE, Thomas S, Ready NE, Granger CL et al.. Prognostic Validation of the Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Index in Inoperable Non-Small-Cell Lung Cancer. J Thorac Oncol. 2013; 8(12):1545-50.
• [53]Steiner M, Singh S, Morgan M. The contribution of peripheral muscle function to shuttle walking performance in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil. 2005; 25(1):43-9.
• [54]Aliverti A, Macklem P. Point: Counterpoint: The major limitation to exercise performance in COPD is: 1) inadequate energy supply to the respiratory and locomotor muscles, 2) lower limb muscle dysfunction, 3) dynamic hyperinflation. J Appl Physiol. 2008; 105(2):749-51.
• [55]Norman K, Stobäus N, Smoliner C, Zocher D, Scheufele R, Valentini L et al.. Determinants of hand grip strength, knee extension strength and functional status in cancer patients. Clin Nutr. 2010; 29(5):586-91.